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Evidence is steadily accumulating that a large number of diseases in which historical 
therapies have made no signiﬁ  cant impact in outcome are suddenly for the ﬁ  rst time 
effectively treated to yield outcomes unimaginable with prior therapies. Because of 
the complexities of signaling mechanisms and variation in these mechanisms between 
disease processes, thorough and standardized testing of efﬁ  cacy and toxicity in each 
predicted therapeutic indication remains mandatory. This is particularly true for tumor 
necrosis factor-alpha (TNFα)-targeting therapies, which may have a role in palliation 
of symptoms of a much more diverse array of diseases than perhaps previously fore-
seen, but can occasionally trigger very signiﬁ  cant adverse effects due to complexity 
of signaling down-stream of TNFα. 
The diversity of biological signaling mechanisms targeted by available therapeutics 
is still a small fraction of potential therapeutic targets. Increasing accuracy in deﬁ  ni-
tion of targets and effects and a remarkable variety of approaches taken to identify and 
target the key factors in the pathogenesis of disease will bring increasingly effective 
novel targeted drugs for individual diseases. The review by deLara and Noble (2007) of 
an intriguing hypothesis for the pathogenesis of asthma points out how evidence from 
varied disciplines has converged. The ‘hygiene hypothesis’ of asthma, supported by a 
wealth of epidemiological studies, suggests that the dramatic increase in incidence of 
asthma is related to reduced antigen exposures in childhood due to improved hygiene. 
Elucidation of the differential response in the Th1/Th2 immune response pathways 
in response to microbial pathogens, and crucial corroborating evidence from genetic 
studies of hereditary asthma, has led to a plausible mechanistic explanation for the 
epidemiological observation. These observations are crucial for rational targeting of 
asthma as well as atopic disorders in general.
Though monoclonal antibodies remain formidable therapeutics as evidenced 
by papers in this issue reviewing their use in treatment of colon cancer, ankylosing 
spondylitis, and psoriasis, the most coveted prizes remain the small molecules with 
favorable pharmacological properties that affects these pathways speciﬁ  cally, having 
only the desired effect and little or no untoward effects. Towards such a goal of ratio-
nal drug-design, imagine a single chemical scaffold useful as a backbone of multiple 
drugs to speciﬁ  cally target several different signaling pathways. Isatin, an endogenous 
MAO inhibitor seems to ﬁ  t this description. Isatin analogs appear to naturally target 
multiple enzymatic pathways involved in inﬂ  ammatory and degenerative disorders. 
Much work still lies ahead in development of this therapeutic to the exquisitely reﬁ  ned 
drug-design which led to the development of nilotinib, a clearly improved drug for 
targeting the best deﬁ  ned target, Bcr-Abl. In contrast to the speciﬁ  city of Bcr-Abl 
signaling, NFκB, an important down-stream element of TNFα signaling, remains 
a very complex centerpiece linked to innumerable events that can lead to different 
outcomes depending on context.
At the other end of the spectrum is a highly logical, direct, and empiric approach 
to therapy without particular regard to a particular protein target, but nevertheless 
targeted anatomically and physiologically to deliver an anticancer immune adjuvant 
effect. The novel approach that has actually been translated into human clinical trial is 
the use of vaccination site-draining lymph node as an immune adjuvant. Although still 
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quite preliminary because of the small number of patients, 
the ﬁ  ndings of response and stable disease in advanced cases 
are of major interest.
References
de Lara C, Noble A. 2007. Dishing the dirt on asthma: what we can learn 
from poor hygiene. Biologics Target Ther, 1:139–50. 